OncoMed files for $115m IPO to advance Phase II clinical trials
This article was originally published in Scrip
Executive Summary
Redwood City, California-based OncoMed Pharmaceuticals filed for a $115 million initial public offering on 11 May, even though the oncology-focused company has more than a year's worth of cash on its balance sheet, to raise capital for three Phase II clinical trials.